We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Experts Discuss What ANDA Filers Can Learn From Takeda Decision
Experts Discuss What ANDA Filers Can Learn From Takeda Decision
January 6, 2009
Generic Line asked Chad Landmon, a partner with the law firm Axinn, Veltrop & Harkrider LLP, and Thomas Hedemann, an associate in the firm’s Hartford office, about what the generic drug industry can learn from a recent decision by the U.S. Court of Appeals for the Federal Circuit that upheld a ruling in Takeda Chemical Industries et al. v. Mylan Laboratories.